A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia

Reginald Bruskewitz, Muta M. Issa, Claus Roehrborn, Michael J. Naslund, Ramon Perez-Marrero, Bryan P. Shumaker, Joseph E. Oesterling

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Purpose: We assess the 1-year efficacy and safety of transurethral needle ablation of the prostate compared to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A prospective, randomized clinical trial of 121 men 50 years old or older with symptomatic BPH was performed at 7 medical centers across the United States. Of the men 65 (54%) were treated with transurethral needle ablation of the prostate and 56 (46%) underwent transurethral resection of the prostate. Mean and percentage changes from baseline and between cohorts for American Urological Association (AUA) symptom score, AUA bother score, quality of life score, peak urinary flow rate and post-void residual urine volume were measured at 1, 3, 6 and 12 months following treatment. Length of procedure, hospitalization, type of anesthesia, post- procedure catheterization, side effects and sexual function were compared. Results: Transurethral needle ablation and resection resulted in a statistically significant improvement in AUA symptom, bother and quality of life scores, peak urinary flow rate and post-void residual. At 1-year followup, needle ablation and resection were equally effective in enhancing quality of life. Needle ablation had less effect on sexual function, with resection being associated with a greater incidence of retrograde ejaculation. Needle ablation could be performed as an outpatient procedure with local anesthesia while resection required anesthesia and hospitalization. Needle ablation was associated with markedly fewer side effects than resection. Conclusions: Compared to transurethral resection of the prostate, transurethral needle ablation of the prostate is an efficacious, minimally invasive treatment for symptomatic BPH that is associated with few side effects.

Original languageEnglish (US)
Pages (from-to)1588-1594
Number of pages7
JournalJournal of Urology
Volume159
Issue number5
StatePublished - May 1998

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Needles
Clinical Trials
Quality of Life
Hospitalization
Therapeutics
Anesthesia
Ejaculation
Residual Volume
Local Anesthesia
Catheterization
Outpatients
Randomized Controlled Trials
Urine
Safety
Incidence

Keywords

  • Prostatic hypertrophy
  • Treatment protocol

ASJC Scopus subject areas

  • Urology

Cite this

A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. / Bruskewitz, Reginald; Issa, Muta M.; Roehrborn, Claus; Naslund, Michael J.; Perez-Marrero, Ramon; Shumaker, Bryan P.; Oesterling, Joseph E.

In: Journal of Urology, Vol. 159, No. 5, 05.1998, p. 1588-1594.

Research output: Contribution to journalArticle

Bruskewitz, Reginald ; Issa, Muta M. ; Roehrborn, Claus ; Naslund, Michael J. ; Perez-Marrero, Ramon ; Shumaker, Bryan P. ; Oesterling, Joseph E. / A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. In: Journal of Urology. 1998 ; Vol. 159, No. 5. pp. 1588-1594.
@article{0f47a707228e40dea1f6d46de111d065,
title = "A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia",
abstract = "Purpose: We assess the 1-year efficacy and safety of transurethral needle ablation of the prostate compared to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A prospective, randomized clinical trial of 121 men 50 years old or older with symptomatic BPH was performed at 7 medical centers across the United States. Of the men 65 (54{\%}) were treated with transurethral needle ablation of the prostate and 56 (46{\%}) underwent transurethral resection of the prostate. Mean and percentage changes from baseline and between cohorts for American Urological Association (AUA) symptom score, AUA bother score, quality of life score, peak urinary flow rate and post-void residual urine volume were measured at 1, 3, 6 and 12 months following treatment. Length of procedure, hospitalization, type of anesthesia, post- procedure catheterization, side effects and sexual function were compared. Results: Transurethral needle ablation and resection resulted in a statistically significant improvement in AUA symptom, bother and quality of life scores, peak urinary flow rate and post-void residual. At 1-year followup, needle ablation and resection were equally effective in enhancing quality of life. Needle ablation had less effect on sexual function, with resection being associated with a greater incidence of retrograde ejaculation. Needle ablation could be performed as an outpatient procedure with local anesthesia while resection required anesthesia and hospitalization. Needle ablation was associated with markedly fewer side effects than resection. Conclusions: Compared to transurethral resection of the prostate, transurethral needle ablation of the prostate is an efficacious, minimally invasive treatment for symptomatic BPH that is associated with few side effects.",
keywords = "Prostatic hypertrophy, Treatment protocol",
author = "Reginald Bruskewitz and Issa, {Muta M.} and Claus Roehrborn and Naslund, {Michael J.} and Ramon Perez-Marrero and Shumaker, {Bryan P.} and Oesterling, {Joseph E.}",
year = "1998",
month = "5",
language = "English (US)",
volume = "159",
pages = "1588--1594",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia

AU - Bruskewitz, Reginald

AU - Issa, Muta M.

AU - Roehrborn, Claus

AU - Naslund, Michael J.

AU - Perez-Marrero, Ramon

AU - Shumaker, Bryan P.

AU - Oesterling, Joseph E.

PY - 1998/5

Y1 - 1998/5

N2 - Purpose: We assess the 1-year efficacy and safety of transurethral needle ablation of the prostate compared to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A prospective, randomized clinical trial of 121 men 50 years old or older with symptomatic BPH was performed at 7 medical centers across the United States. Of the men 65 (54%) were treated with transurethral needle ablation of the prostate and 56 (46%) underwent transurethral resection of the prostate. Mean and percentage changes from baseline and between cohorts for American Urological Association (AUA) symptom score, AUA bother score, quality of life score, peak urinary flow rate and post-void residual urine volume were measured at 1, 3, 6 and 12 months following treatment. Length of procedure, hospitalization, type of anesthesia, post- procedure catheterization, side effects and sexual function were compared. Results: Transurethral needle ablation and resection resulted in a statistically significant improvement in AUA symptom, bother and quality of life scores, peak urinary flow rate and post-void residual. At 1-year followup, needle ablation and resection were equally effective in enhancing quality of life. Needle ablation had less effect on sexual function, with resection being associated with a greater incidence of retrograde ejaculation. Needle ablation could be performed as an outpatient procedure with local anesthesia while resection required anesthesia and hospitalization. Needle ablation was associated with markedly fewer side effects than resection. Conclusions: Compared to transurethral resection of the prostate, transurethral needle ablation of the prostate is an efficacious, minimally invasive treatment for symptomatic BPH that is associated with few side effects.

AB - Purpose: We assess the 1-year efficacy and safety of transurethral needle ablation of the prostate compared to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A prospective, randomized clinical trial of 121 men 50 years old or older with symptomatic BPH was performed at 7 medical centers across the United States. Of the men 65 (54%) were treated with transurethral needle ablation of the prostate and 56 (46%) underwent transurethral resection of the prostate. Mean and percentage changes from baseline and between cohorts for American Urological Association (AUA) symptom score, AUA bother score, quality of life score, peak urinary flow rate and post-void residual urine volume were measured at 1, 3, 6 and 12 months following treatment. Length of procedure, hospitalization, type of anesthesia, post- procedure catheterization, side effects and sexual function were compared. Results: Transurethral needle ablation and resection resulted in a statistically significant improvement in AUA symptom, bother and quality of life scores, peak urinary flow rate and post-void residual. At 1-year followup, needle ablation and resection were equally effective in enhancing quality of life. Needle ablation had less effect on sexual function, with resection being associated with a greater incidence of retrograde ejaculation. Needle ablation could be performed as an outpatient procedure with local anesthesia while resection required anesthesia and hospitalization. Needle ablation was associated with markedly fewer side effects than resection. Conclusions: Compared to transurethral resection of the prostate, transurethral needle ablation of the prostate is an efficacious, minimally invasive treatment for symptomatic BPH that is associated with few side effects.

KW - Prostatic hypertrophy

KW - Treatment protocol

UR - http://www.scopus.com/inward/record.url?scp=0032459837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032459837&partnerID=8YFLogxK

M3 - Article

C2 - 9554360

AN - SCOPUS:0032459837

VL - 159

SP - 1588

EP - 1594

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -